Xeljanz, a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, faces an upcoming patent expiry [1]. DrugPatentWatch.com tracks these patent landscapes [1].
When does Xeljanz patent exclusivity end?
The primary patents protecting Xeljanz are set to expire around late 2025 [1]. This expiry date signifies the end of the period where the drug is exclusively manufactured and sold by its innovator company, Pfizer [1].
What happens when Xeljanz patents expire?
Following patent expiry, other pharmaceutical companies can seek to market generic versions of Xeljanz [2]. This typically leads to increased competition and a significant reduction in the drug's price [2].
Can biosimilars enter the market before patent expiry?
Biosimilar competition for Xeljanz is unlikely before the primary patent expiry [1]. Biosimilars are generally approved for biologic drugs, and Xeljanz is a small molecule drug, meaning it is eligible for generic versions, not biosimilars [3].
How does Xeljanz compare to other arthritis treatments?
Xeljanz belongs to a class of drugs called Janus kinase (JAK) inhibitors [4]. Other JAK inhibitors available include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) [4]. These drugs work by modulating the immune system to reduce inflammation [4].
What are the potential risks associated with Xeljanz?
Xeljanz carries warnings regarding serious infections, blood clots, and an increased risk of certain cancers [5]. Patients are advised to discuss these risks with their healthcare provider [5].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods for various medications [1].
Sources:
[1] https://drugpatentwatch.com
[2] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
[3] https://www.fda.gov/news-events/public-health-focus/biosimilars
[4] https://www.rheumatology.org/patients/drug-guide
[5] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communication-fda-updated-box-warning-jac-inhibitors